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Objectives: A growing body of evidence suggests that the microbiome plays an important role in 
mental health. Few studies have examined how probiotic supplementation affects sleep quality. 
The current study investigated the impact of probiotics on self-reported sleep quality and the role 
of anxiety in moderating this relationship. The study also assessed the role of vagal tone in 
mediating probiotic-induced improvements in self-reported sleep quality. 
 
Methods: Forty-three undergraduates at the University of Kansas participated in a two-week 
study assessing the effect of probiotic supplementation on psychological and physiological 
processes. A sleep diary was collected daily. Measures of sleep, anxiety, and vagal tone were 
collected at baseline and post-intervention. Indices of sleep quality were analyzed using 
multilevel growth modeling. The moderating effects of treatment condition and initial anxiety 
were examined. The meditating effect of vagal tone was also assessed. 
 
Results: Initial level of anxiety was found to moderate the effect of probiotic supplementation on 
sleep onset latency (SOL) and sleep efficiency. In participants without elevated anxiety, 
probiotic supplementation was associated with a significant decrease in SOL and a significant 
increase in sleep efficiency over the course of the two-week trial. The effectiveness of probiotic 
supplementation increased as anxiety decreased. Probiotic supplementation had no effect on SOL 
and sleep efficiency in participants with elevated levels of anxiety. No association was found 
between treatment condition and number of awakenings or minutes awake after sleep onset. 




Conclusion: These findings suggest that the microbiome influences sleep quality. Manipulation 
of the microbiome via probiotic supplementation may be useful for treating individuals with 
disrupted sleep. 
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The Effect of Probiotic Supplementation on Self-Reported Sleep Quality 
The study of the microbiome and probiotics is a rapidly growing area in the fields of 
physical and mental health. The microbiome is the collection of approximately 100 trillion 
microorganisms found in the human gastrointestinal tract (Galland, 2014). This “microbial 
organ” contains a vast amount of genetic material and forms a symbiotic relationship with its 
host (Backhed, Ley, Sonnenburg, Peterson, & Gordon, 2005). The microbiome assists in 
harvesting otherwise inaccessible nutrients, such as cellulose and resistant starches (Backhed et 
al., 2005). It also supports the development of the immune system (Nikoopour & Singh, 2014). 
Formation of the microbiome begins prenatally and is strongly influenced by environmental 
factors (Li, Wang, & Donovan, 2014). 
Unfortunately, modern lifestyles are detrimental to the microbiome. Due to the built 
environment, humans are no longer receiving exposure to the microorganisms necessary for a 
healthy microbiome (Hoisington, Brenner, Kinney, Postolache, & Lowry, 2015). Widespread 
antibiotic usage also plays a major role in promoting microbiome dysfunction (Blaser, 2016). 
Emerging evidence suggests this dysfunction can lead to a number of diseases (de Vos & de Vos, 
2012). Alterations in the diversity of intestinal microbiota have been linked to health aberrations 
such as inflammatory bowel disease, obesity, and allergies (Kaser, Zeissig, & Blumberg, 2010; 
Ley, Turnbaugh, Klein, & Gordon, 2006; Stsepetova et al., 2007). Sudo et al. (2004) found that 
germfree mice—mice raised without exposure to microorganisms—displayed an exaggerated 
stress response. A disrupted circadian rhythm, in combination with a high-fat, high-sugar diet, 
has also been shown to alter the microbiome in mice (Voigt et al., 2014). This finding is 
particularly relevant as it represents modern sleeping and dieting habits.  
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One way of therapeutically altering the microbiome is through probiotics. Probiotics are 
microorganisms that improve the health of the host when administered (Williams, 2010). 
Products containing probiotics are abundantly available, and easily accessible by the general 
population. According to Williams (2010), the two most common species of bacteria used in 
probiotics are Lactobacillus (L.) and Bifidobacterium (B.): However, effects seem to depend on 
the specific strain. Rather than causing permanent change, probiotics tend to temporarily 
colonize the intestines (Alander et al., 1999). While primarily studied in patients with irritable 
bowel syndrome, emerging evidence suggests that probiotics may have psychotropic properties 
(Dinan, Stanton, & Cryan, 2013).  
Probiotics can interface with the brain through the microbiome-gut-brain axis, a 
communication system involving both humoral and neural pathways (Bercik, Collins, & Verdu, 
2012; Mayer, 2011). This exchange is bidirectional and allows reciprocal regulation between the 
gut and the brain (Cryan & O'Mahony, 2011). Microbiota can affect inflammatory and immune 
processes, as well as produce hormones and neurotransmitters (for review see Galland, 2014). By 
doing so, these organisms are capable of influencing the central nervous system. The 
microbiome is also closely associated with the enteric nervous system, which is the 200 to 600 
million neurons of the gut considered to be the third branch of the autonomic nervous system 
(Mayer, 2011). The vagus nerve—a primary component of the parasympathetic nervous 
system—serves as a primary connection between the enteric and central nervous system, 
innervating foregut structures (Mayer, 2011). The vagus nerve will be discussed in greater detail 
later in this paper. 
Recent studies have demonstrated the connection between probiotics and mental health. 
Treatment with L. helveticus and B. longum has been linked to reduction in stress, depression and 
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anxiety in both animals and humans (Ait-Belgnaoui et al., 2014; Gilbert et al., 2013; Messaoudi 
et al., 2011). Benton, Williams, and Brown (2007) demonstrated that mood was significantly 
improved in low-mood individuals after administration of an L. casei milk drink. In animal 
models, Bifidobacterium infantis has been found to reduce pro-inflammatory responses and 
provide possible antidepressant effects through increased tryptophan release (Desbonnet, Garrett, 
Clarke, Bienenstock, & Dinan, 2008). Ingestion of this strain has also been shown to reduce 
depressive behaviors, restore immune function and basal noradrenaline concentrations in rats 
following maternal separation (Desbonnet et al., 2010). In a study by Kantak, Bobrow, and Nyby 
(2014), treatment with L. rhamnosus GG was comparable to medication in attenuating OCD-like 
behavior in mice. These “psychobiotics” could represent a new form of treatment for 
psychological symptoms (Dinan et al., 2013). 
Probiotics and Sleep Quality 
Very little research has examined the effect of probiotics on sleep. Sleep is vital for 
normal physiological and psychological functioning. Unfortunately, 50-70 million Americans 
experience disordered sleep, inflicting substantial financial and societal cost (Institute of 
Medicine Committee on Sleep & Research, 2006). Sleep disturbance is a significant stressor that 
contributes to cognitive impairment, affective disruption and physical disease (McEwen, 2006). 
Mood or anxiety disorders are often comorbid in people with chronic insomnia (Kraus & Rabin, 
2012). Modern lifestyles contribute to this growing health concern by shifting importance away 
from healthy sleep habits and towards other activities. Developing effective and safe treatments 
for disturbed sleep is a necessary public priority. 
There is some preliminary, albeit inconclusive, evidence that probiotics can improve 
sleep. Mice treated with heat-killed L. brevis showed alterations in sleep patterns, which could 
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potentially treat disrupted sleep rhythms (Miyazaki et al., 2014). Yamamura et al. (2007) 
demonstrated that ingestion of an L. helveticus drink significantly improved sleep efficiency and 
number of wakening episodes in elderly patients when compared to baseline values. However, 
probiotics did not outperform placebo in this study. Furthermore, Diop, Guillou, and Durand 
(2008) demonstrated that treatment for three weeks with L. acidophilus and B. longum did not 
improve sleep symptoms, but did alleviate stress-related gastrointestinal symptoms. As it stands, 
the relationship between probiotics and sleep is still poorly understood. It should be noted that 
current studies have not looked at individuals with preexisting sleep difficulties. More severe 
sleep disturbance may make the therapeutic effects of probiotics more noticeable. For example, 
one study has found that probiotics improve mood, but only in individuals with poor mood at the 
start of the study (Benton et al., 2007). As such, given the findings that probiotics can positively 
affect psychological processes, it is expected that probiotic supplementation would have positive 
effects in people experiencing sleep disturbance. 
Hypothesis 1: Probiotic supplementation will improve self-reported sleep quality in 
individuals with poor sleep. 
Anxiety as a Moderating Factor 
The relationship between the microbiome and disrupted sleep may involve other 
psychological processes. Anxiety, which is known to contribute to poor sleep, is of particular 
interest (Altun, Cinar, & Dede, 2012; Mirbagher, Gholamrezaei, Hosseini, & Sayed Bonakdar, 
2014). Anxiety disorders tend to precede the development of insomnia, a relationship not seen in 
mood disorders (Johnson, Roth, & Breslau, 2006; Ohayon & Roth, 2003). Treatment of sleep 
disturbance is an important goal when treating generalized anxiety disorder, and medications 
managing anxiety symptoms can also improve sleep (Sheehan, Svedsater, Locklear, & Eriksson, 
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2013). Concurrent improvements in anxiety and sleep can also be seen in other therapies (Bradt, 
Dileo, & Potvin, 2013; Cho, Min, Hur, & Lee, 2013; Clementi & Alfano, 2014). The close 
relationship between anxiety and sleep disturbance highlights the need to assess anxiety when 
investigating new sleep treatments.  
As mentioned briefly in a previous section, certain strains of probiotics have been found 
to contain anxiolytic properties. Further evidence of this can be seen in recent animal model 
studies. L. helveticus interacts with genotype and diet to protect against anxiety in certain types 
of mice (Ohland et al., 2013). Heightened anxiety-like behavior in immunocompromised mice 
was normalized by administration of L. rhamnosus and L. helveticus (Smith et al., 2014). 
Administration of L. helveticus in rats also reduced anxiety-like behavior while reducing 
neruoinflammation and restoring serotonin transmission (Luo et al., 2014). Keeping this in mind, 
it is expected that probiotic supplementation would have a greater effect in improving disturbed 
sleep in individuals also presenting with heightened anxiety. This is because of the potential of 
probiotics to address disrupted sleep through multiple avenues of action. Individuals with high 
anxiety may present more opportunities for probiotics to have a therapeutic effect via anxiety-
related and anxiety-unrelated pathways. In essence, probiotics would be capable of taking a 
multi-targeted approach to addressing disrupted sleep.  
Hypothesis 2: Anxiety will moderate the beneficial effects of probiotics on sleep, and 
higher anxiety prior to treatment will relate to greater improvement in self-reported sleep 
quality.  
The Role of the Vagus Nerve 
Finally, it is important to understand how probiotics may influence disrupted sleep. As 
mentioned previously, the vagus nerve is a component of the microbiome-gut-brain axis. 
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Forsythe, Kunze, and Bienenstock (2012) have suggested that the vagus nerve is crucial in 
mediating the effects of microbiota on the brain of animals. Vagal restriction prevented 
probiotic-induced reduction of anxiety- and depression-related behavior in mice (Bravo et al., 
2011). Bercik et al. (2011) also demonstrated the importance of vagal integrity in mediating 
probiotic-induced anxiolysis. These findings have marked vagal tone as a primary candidate of 
interest when assessing probiotic mechanisms of action. 
One way to assess vagal tone is through measurement of heart rate variability (HRV), or 
the variation of the intervals between heart beats. HRV is highly dependent upon vagal input, 
particularly during respiratory sinus arrhythmia (Chess, Tam, & Calaresu, 1975; Porges, 
Doussard-Roosevelt, & Maiti, 1994). Respiratory sinus arrhythmia (RSA) is characterized by an 
increase in heart rate during inspiration and a decrease in heart rate during expiration (Grossman 
& Taylor, 2007). RSA can be assessed through spectral analysis of heart rate. Spectral analysis 
separates the variance of the signal into three discrete frequency bands: very low frequency 
(VLF), low frequency (LF), and high frequency (HF; European Society of Cardiology, 1996). 
High-frequency HRV (henceforth referred to as HF) is the frequency that corresponds with RSA, 
and therefore is widely accepted as an index of vagal tone (for review see European Society of 
Cardiology, 1996). High HF during resting conditions is thought to reflect a physiologically 
flexible state that facilitates adaptive response to stressors (Tonhajzerova, Mokra, & Visnovcova, 
2013). This flexibility is also important for healthy psychological processes, such as emotional 
regulation and attention (Porges et al., 1994). 
Reduced HF is associated with a multitude of mental health disorders. Hughes and 
Stoney (2000) found that depressed mood is related to a greater decrease in HF during stress. A 
recent meta-analysis also linked major depressive disorder with reduced HF, along with a shift 
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towards sympathetic dominance reflected by other measures of HRV (Kemp et al., 2010). 
Alcohol dependence is associated with reduced HF, and alcohol use negatively correlates with 
HF in college students (Quintana, McGregor, Guastella, Malhi, & Kemp, 2013; Udo et al., 
2013). Post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, and several types 
of anxiety disorder are all related to decreased HF as well (Minassian et al., 2014; Moon, Lee, 
Kim, & Hwang, 2013; Pittig, Arch, Lam, & Craske, 2013; Wahbeh & Oken, 2013). 
While sleep is controlled through multiple mechanisms, the parasympathetic nervous 
system plays a prominent regulatory role. Toscani et al. (1996) and Baharav et al. (1995) 
demonstrated that HF increases continuously from sleep onset and reaches its highest value 
during slow-wave sleep. Parasympathetic control is strongest during these phases. During the 
REM phase, the sympathetic system gains dominance, and HF is greatly reduced (Cabiddu, 
Cerutti, Viardot, Werner, & Bianchi, 2012). This constantly shifting balance is indicative of a 
healthy autonomic nervous system and a normal sleep cycle. 
A growing body of evidence exists connecting suppressed parasympathetic activity to 
sleep disturbance. Individuals with PTSD and disturbed sleep had significantly reduced HF 
compared to PTSD-resilient individuals (Kobayashi, Lavela, & Mellman, 2014). Self-reported 
sleep quality correlates with HF, and disrupted sleep in children is associated with decreased HF 
(El-Sheikh, Erath, & Bagley, 2013; Hovland et al., 2013; Michels et al., 2013). People with 
primary insomnia have been shown to have increased beta electroencephalography activity and 
lower HF HRV in slow-wave sleep, suggesting a state of hyperarousal (Maes et al., 2014). 
Overall, it appears that disrupted sleep is associated, at least in part, with disruption in autonomic 
balance: specifically, a shift towards increased sympathetic activity and decreased 
parasympathetic activity. Introduction of beneficial bacteria to GI tract would be expected to 
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increase vagal tone via the microbiome-gut-brain axis. As a result, this probiotic-induced vagal 
activity should restore autonomic balance and therefore improve sleep quality. 
Hypothesis 3: The beneficial effect of probiotics will improve vagal tone assessed by 




Participants were undergraduate students recruited from the University of Kansas SONA 
research pool. Undergraduates were targeted both as a sample of convenience and because 
disrupted sleep is a widespread problem for this population (Hershner & Chervin, 2014). The 
SONA research pool consists of all students currently enrolled in Psychology 104 who have 
opted to participate in research. As this is part of a larger study, all participants were selected 
based on the dysphoric criteria of scoring greater than 10 on the Beck Depression Inventory 
(BDI; Beck, Steer, & Brown, 1996) during the SONA pre-screening survey. Participants were 
included in this study if they presented with a Pittsburgh Sleep Quality Index (PSQI) total value 
greater than 5—a score associated with poor sleep quality—during the initial study session 
(Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). Fifty-two participants were eligible for this 
study. Data were available for 44 participants who completed the initial session and at least three 
sleep diaries during the supplementation period. One participant was an outlier (average value of 
sleep onset latency greater than 3 standard deviations from the overall mean) and was excluded 
from the data analysis. The final data analysis was conducted with 43 participants. 
Because of the nature of participant selection, I was not able to fully control for equal 
group assignment beforehand. However, the main study used a randomized block design with a 
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block size of four to assign participants to a study condition. This meant that two out of every 
four participants were assigned to the same treatment condition. As such, participants were 
almost equally assigned to each condition in this study (n = 20 for placebo; n = 23 for probiotic). 
Study Treatment 
 Probiotic supplementation consisted of one dose (two capsules) of regular PB8 (Nutrition 
Now, Vancouver, WA). Bacteria strains in this product included L. acidophilus, L. plantarum, L. 
salivarius, L. rhamnosus, L. casei, B. lactis, B. bifidum, and B. longum. Excipients were 
microcrystalline cellulose, inulin, magnesium stearate, and silica. PB8 contains 14 billion 
colony-forming units per dose. Placebo pills consisted of microcrystalline cellulose-filled 
capsules matched as closely as possible in size and shape to the PB8 capsules.  
Instruments 
Beck Depression Inventory—II.  The BDI—II (Beck et al., 1996) is a 21-item self-
report measure assessing depression severity. The intensity of each symptom is scored 0 to 3, 
with higher scores indicating greater severity of depression. The BDI demonstrates high 
reliability (Cronbach’s α = .81-.86) and validity (Beck, Steer, & Carbin, 1988). 
Pittsburgh Sleep Quality Index. Sleep quality was assessed through a modified PSQI (Buysse 
et al., 1989). The PSQI is a 19-item self-report measure assessing sleep quality across seven 
domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep 
disturbances, use of sleep medication, and daytime dysfunction. The PSQI has acceptable 
reliability and validity (Buysse et al., 1989). The PSQI was modified to reflect sleep habits over 
the past two weeks, rather than the past month. 
Sleep diary. The sleep diary was a 17-item self-report measure assessing different 
aspects of sleep during the previous night. The sleep diary used in this study was based off of the 
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Core Consensus Sleep Diary (CSD: Carney et al., 2012). The CSD was designed to standardize 
sleep self-monitoring. 
State portion of the State-Trait Anxiety Inventory (STAI). The STAI consists of two 20-item 
self-report measures assessing state and trait anxiety severity (Spielberger, Gorsuch, Lushene, 
Vagg, & Jacobs, 1983). Items are rated on a 4-point scale with higher scores indicating greater 
anxiety. The STAI has high reliability and validity (Spielberger, 1989; Spielberger et al., 1983). 
The state portion of the STAI has been shown to be efficacious in detecting mental health 
disorders (Kvaal, Ulstein, Nordhus, & Engedal, 2005). 
Heart rate variability. HRV was collected through a three-lead electrocardiogram (ECG; 
MindWare Technologies LTD., Gahanna, OH), using Ag/AgCl disposable electrodes and a 
sample rate of 1000 Hz. During the ECG data collection, participants were seated and 
performing a vanilla baseline task, which has been shown to improve between- and within-
subject stability (Jennings, Kamarck, Stewart, Eddy, & Johnson, 1992; Udo et al., 2013). The 
vanilla baseline task required participants to count the number of times a rectangle of a certain 
color appeared on a screen, in order to create a standardized resting condition across participants. 
Task stimuli were created and presented using the E-prime software (Psychology Software 
Tools, Pittsburgh, PA). During the initial session, participants counted the number of blue 
rectangles; during the follow-up session, participants counted the number of purple rectangles. 
The 10-minute recording window was separated into two 5-minute intervals. The first interval 
was used to initiate a resting state and the second interval used to assess HRV.  
 HRV was collected and analyzed using HRV Analysis Software (MindWare 
Technologies LTD., Gahanna, OH). ECG data was visually inspected and manually corrected for 
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missing or skipped beats, artifacts, and misidentified R-peaks. HF power was selected as the 
measured variable.  
Procedure 
 This study consisted of an initial session (Day 0), a 14-day supplementation period (Days 
1-14), and a final session (Day 14 after final probiotic administration). The length of 
supplementation period was chosen based off of previous study methodology (Ait-Belgnaoui et 
al., 2014; Desbonnet et al., 2008). The initial and final session took place on the same day of the 
week, and as close to the same time as possible. During the initial session, participants were 
consented to the study. HRV was then collected, followed by questionnaire administration. 
Finally, participants were given their supply of study treatment, along with instructions 
concerning administration and performance of the adherence check. The entire process lasted 
approximately one hour. Experimenters and participants were blind to the assigned treatment 
condition. 
 The supplementation period began the day following the initial session. Participants took 
one dose of study treatment in the morning of each day. They then filled out the daily online 
sleep diary. An adherence check was included at the end of the sleep diary, which required the 
participant to upload a photo of him/herself taking the supplement. On Day 14, participants took 
their last dose in the morning prior to arriving at the final session. The final session consisted of 
HRV and questionnaire collection, identical to the first session. At the end of the session, 
participants were given a debriefing form, explaining the purpose of the study.  
Statistical Analysis 
Analyses were conducted using the lme4, glmmADMB and mediation packages in R 
3.2.5 (Bates, Maechler, Bolker, & Walker, 2015; Fournier et al., 2012; R Core Team, 2016; 
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Tingley, Yamamoto, Hirose, Keele, & Imai, 2014). Sleep onset latency (SOL), number of 
awakenings, waking after sleep onset (WASO), and sleep efficiency were used as outcomes and 
were modeled as discrete Poisson variables. Sleep efficiency was modeled by using the total 
number of minutes asleep as the outcome variable and the log of total time in bed (SOL + 
minutes asleep + WASO + minutes in bed after awakening) as an offset variable. Examination of 
the distributions of the number of awakenings and WASO variables revealed a large quantity of 
responses valued at zero. To address this, models were corrected for zero inflation (Harrison, 
2014). An alpha level of .05 was selected to test model estimate significance. Multilevel growth 
models (MGMs) were used to assess change in the outcome variables over the course of the 
study. Multilevel models are useful in analyzing grouped observations. A classic example of 
multilevel modeling involves assessing characteristics of students within classrooms. Students 
represent a level-1 variable, while the classroom to which a student belongs represents a level-2 
variable. It is expected that students are more similar to their classroom-peers than to students in 
other classrooms. Multilevel modeling is a form of analysis that allows random effects to be 
estimated, which can account for variance unique to the grouping level. MGMs are an extension 
of this. In MGMs, repeated observations from an individual represent the level-1 variables, while 
the attributes of the individual represent level-2 variables. This type of analysis is useful in 
determining how between-individual variables (such as experimental condition) affect within-
individual measurements over time. 
For this study, four two-level MGMs were computed. Sleep onset latency (in minutes), 
number of awakenings, WASO (in minutes), and sleep efficiency were modeled separately as 
dependent variables. Observation-level random effects were utilized in the sleep onset latency 
model to correct for overdispersion (Harrison, 2014). For each model, predictor variables 
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included day of observation (Level 1), as well as study condition and initial STAI score (Level 
2). Models were specified according to Bliese (2013) with values for day of observation 
representing the number of days since the start of treatment (i.e., 0, 1, 2, 3…). An interaction 
between time, treatment condition, and initial anxiety was estimated. A significant interaction 
estimate indicated that study condition and initial STAI score moderate change in the dependent 
variable over time. Appropriate lower order interactions were also estimated. Participant age and 
use of sleep medication were included as covariates to control for their effects. All models 
included a random intercept at the participant level. 
Comparison between pre-treatment and post-treatment STAI, PSQI, and HF power values 
were each assessed using a two-factor repeated analysis of variance. The interaction between 
time and treatment condition was examined. Changes in PSQI subscales were assessed using 
Mann-Whitney U tests. One participant did not complete a follow-up session; therefore, data 
from 42 participants were available to compare pre- and post-treatment STAI and PSQI. 
Technical difficulties during HRV measurement meant that data from 37 participants were 
available to compare pre- and post-treatment HF power. Mediation analysis was performed in 
accordance with the procedures outline by Imai, Keele, and Tingley (2010). Treatment condition 
was selected as the independent variable, while change in PSQI scores was selected as the 
dependent variable. Change in HF power was selected as the mediator variable. A mediator 
model (mediator variable regressed on independent variable) and an outcome model (dependent 
variable regressed on independent and mediator variables) were estimated. Bootstrapping was 




 Descriptive statistics are provided in Table 1. Participants were similar in starting 
characteristics across groups. The average initial sleep onset latency (SOL) for participants was 
26.7 minutes (M placebo = 28.6 minutes, M probiotic = 25.0 minutes). These findings match 
previous studies of disturbed sleep in college students (Lund, Reider, Whiting, & Prichard, 
2010). The average initial number of awakenings was 1.3 (M placebo = 1.2, M probiotic = 1.5), 
the average initial waking after sleep onset (WASO) was 12.5 minutes (M placebo = 10.2, M 
probiotic = 14.6), and the average initial sleep efficiency was 89.2% (M placebo = 88.7%, M 
probiotic = 89.6%). Participants had comparable scores on the BDI (M placebo = 19.7; M 
probiotic = 19.1) and the STAI (M placebo = 45.6; M probiotic = 47.5). A total of 11 participants 
(n placebo = 6; n probiotic = 5) used a sleep aid at least once throughout the study. For these 
participants, the average number of days a sleep aid was used was 7.09 (placebo = 4.67; 
probiotic = 10). The average number of adherence checks submitted, out of a possible 14, was 
12.7 (M placebo = 12.6; M probiotic = 12.8).   
First, a model for SOL was estimated. Results for the model can be found in Table 2. The 
interaction between study day, treatment condition, and initial STAI score was found to be 
statistically significant (β = 0.041±0.018, p = .023), indicating that the change in SOL over time 
is moderated by a combination of treatment condition and initial anxiety. In order to further 
explore the interaction between time, treatment condition, and initial anxiety, secondary analyses 
were performed for all models in which the interaction was significant. Each model was applied 
to two subsets of the data: one containing only participants with initial anxiety below the sample 
median of 47 (representing non-elevated anxiety), and one containing only participants with 
initial anxiety equal to or above the sample median (representing elevated anxiety). The purpose 
of each secondary analysis was to identify if the estimated relationship from the primary analysis 
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was true for both non-elevated and elevated anxiety participants. A significant interaction 
estimate in the secondary analysis indicated that the relationship applied to the corresponding 
sample subset.  
Secondary analyses revealed that the three-way interaction for the SOL model was only 
statistically significant for non-elevated anxiety participants (β = 0.146±0.041, p < .001). There 
was no difference between treatment conditions at elevated levels of anxiety (β = 0.019±0.050, p 
= .708). Further detail regarding the interaction was obtained by estimating SOL reduction over 
the study given conditional values of initial anxiety. Conditional STAI scores were chosen based 
on the 1st quartile value (STAI score = ~39) and the average value (STAI score = ~47). 
Estimated SOL recovery values are displayed in Table 3. Individuals with lower anxiety (1st 
quartile STAI score) receiving probiotic supplementation are expected to experience a 45.19% 
decrease in SOL over two weeks compared to an 8.05% decrease for individuals receiving a 
placebo. Individuals with average anxiety receiving probiotic supplementation are expected to 
experience a 36.05% decrease in SOL compared to a 31.61% decrease for individuals receiving a 
placebo. Probiotic supplementation is more effective than placebo across lower through average 
initial STAI values. This effectiveness is not present at elevated levels of initial anxiety. A 
hypothetical recovery trajectory for a lower-anxiety participant can be viewed in Figure 1. 
Number of awakenings and WASO were also modeled using the same procedure as SOL. 
The interaction between study day, treatment condition, and initial STAI score was not found to 
be statistically significant for either the number of awakenings model (β = 0.002±0.022, p = 
.930) or WASO model (β = 0.013±0.010, p = .208). The interaction between treatment condition 
and time was also not found be statistically significant for either the number of awakenings 
model (β = 0.041±0.022, p = .062) or WASO model (β = 0.010±0.011, p = .376). 
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Finally, a model for sleep efficiency was estimated. Results for this model can be seen in 
Table 2. The interaction between study day, treatment condition, and initial STAI score was 
found to be statistically significant (β = -0.004±0.002, p = .042), indicating that the change in 
sleep efficiency over time is moderated by a combination of treatment condition and initial 
anxiety. Secondary analyses revealed that this interaction was only statistically significant for 
non-elevated anxiety participants (β = -0.011±0.005, p = .044). There was no difference between 
treatment conditions at high initial levels of anxiety (β = 0.000±0.005, p = .918). Sleep efficiency 
increase over the course of the study was also estimated for the same conditional values of initial 
anxiety as used for the SOL model. Estimated sleep efficiency improvement values are displayed 
in Table 4. Individuals with lower anxiety receiving probiotic supplementation are expected to 
experience a 4.41% increase in sleep efficiency over two weeks compared to a 1.40% increase 
for individuals receiving a placebo. Individuals with average anxiety receiving probiotic 
supplementation are expected to experience a 2.67% increase in sleep efficiency compared to a 
4.17% increase for individuals receiving a placebo. Similar to the SOL model, probiotic 
supplementation is more effective than placebo at improving sleep efficiency at lower levels of 
initial anxiety. This effectiveness decreases as initial anxiety decreases and becomes negligible at 
average levels of anxiety. There is no difference between treatment conditions at elevated levels 
of initial anxiety. A hypothetical recovery trajectory for lower-anxiety participant can be viewed 
in Figure 2. 
The interaction between time and probiotic supplementation did not have a statistically 
significant effect on STAI-measured anxiety, F(1,41) = 1.311, p = .259, PSQI-measured sleep, 
F(1,41) = .44, p = .511, or HF power, F(1,36) = 1.375, p = .248. Post-treatment STAI (M 
placebo = 43.9, M probiotic = 48.0) and PSQI (M placebo = 9.3, M probiotic = 9.9) scores were 
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similar between groups. Probiotic supplementation did not have a significant effect on any PSQI 
subscale (p > .05 for all comparisons). Change in HF power did not mediate the relationship 
between treatment condition and sleep. The average mediation effect estimate is 0.02, 95% CI = 
-0.69-0.41, p = .91. The average direct effect estimate is -0.36, 95% CI = -2.01-1.48, p = .79. It 
should be noted that it was hypothesized that probiotic supplementation would improve PSQI-
measured sleep quality and that HF power would act as a mediator on this effect. HF power 
would not be expected to act as a mediator without improvement on the PSQI. 
Discussion 
 The primary goal of this placebo-controlled, double-blind investigation was to evaluate 
the degree to which supplementation with a commercial-grade probiotic could be effective in 
improving self-reported sleep quality in college undergraduates. Multilevel growth modeling was 
used to estimate change in four daily sleep diary metrics—sleep onset latency (SOL), the number 
of awakenings, waking after sleep onset (WASO), and sleep efficiency—over the course of the 
two-week study period.  
Hypothesis 1 predicted that probiotic supplementation would improve self-reported sleep 
quality over placebo. Probiotic supplementation was not observed to have a significant main 
effect on any of the self-reported sleep parameters. This is most likely due to the interaction 
between treatment condition and initial anxiety. Hypothesis 2 predicted that probiotic 
supplementation would lead to a greater improvement of sleep quality in participants with higher 
initial anxiety. While initial anxiety did moderate the effect of treatment, the moderation was 
opposite of the hypothesized direction. Participants without elevated initial anxiety who received 
probiotic supplementation experienced a greater reduction in SOL over the course of the study 
compared to those who received placebo. This difference became greater as initial anxiety 
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decreased. The average lower-anxiety (1st quartile initial anxiety score) participant in the 
probiotic treatment condition experienced a 45.19% reduction in SOL (Table 3), equivalent to a 
12.1-minute reduction. The average lower-anxiety participant in the placebo condition 
experienced only an 8.05% reduction in SOL, equivalent to 2.1-minute reduction. This means 
that there was a 37.14% (10-minute) difference in self-reported SOL change between treatment 
conditions for lower-anxiety participants. Secondary analyses revealed that there was no 
difference between treatment conditions in participants with elevated initial anxiety. 
Similar results were seen regarding sleep efficiency. Probiotic supplementation was 
associated with significantly reduced sleep efficiency in lower-anxiety participants compared to 
placebo. The average lower-anxiety participant in the probiotic treatment condition experienced 
a 4.41% improvement in sleep efficiency, whereas the average lower-anxiety participant in the 
placebo treatment condition experienced a 1.4% increase in sleep efficiency (Table 4). Given a 
starting sleep efficiency of 89.66%, this equates to a 3.95% addition in sleep efficiency in the 
probiotic condition and only a 1.26% addition in sleep efficiency in the placebo condition. 
Again, probiotic supplementation had no effect on participants with elevated initial anxiety. 
These findings are broadly consistent with a previous report suggesting that the ingestion of 
beneficial food-based bacteria may help treat disrupted sleep (Yamamura et al., 2007). 
Treatment condition was not found to be associated with any significant changes in the 
number of awakenings, or on the duration of wakefulness after sleep onset (WASO), over the 
course of this study. Notably, this is the first reported investigation of the effect of probiotic 
supplementation on either self-reported awakenings or WASO. Given the beneficial effect of 
probiotic supplementation on self-reported SOL and sleep efficiency, it is possible that self-
report has insufficient sensitivity to detect probiotic-induced changes in number of awakenings 
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or WASO. Other measures of sleep disturbance, such as actigraphy or polysomnography may be 
of more use in detecting change in these indices.  
The magnitude of the probiotic treatment effect in this study is comparable to some 
previously reported effects of active treatments for insomnia. For example, a meta-analysis by 
Huedo-Medina, Kirsch, Middlemass, Klonizakis, and Siriwardena (2012) found that, on average, 
non-benzodiazepine hypnotics decreased self-reported SOL by seven minutes over placebo—
remarkably similar to the 9.8-minute reduction observed with supplementation in lower-anxiety 
participants in the present study. Likewise, cognitive-behavioral therapy for insomnia has been 
found to reduce self-reported SOL by 8.4 minutes, improve sleep efficiency by 17%, and to 
improve other indices of disrupted sleep by 25-50% in elderly patients with insomnia (Kay, 
Buysse, Germain, Hall, & Monk, 2015). Sleep restriction therapy has been found to reduce self-
reported SOL by roughly 16 minutes over placebo, increase sleep efficiency by 17% over 
placebo, and reduce other measures of sleep disturbance by approximately 50% (Miller et al., 
2014). The magnitude of the effect of probiotic supplementation on sleep efficiency was not as 
great in the present study as the other treatments. However, it should be noted that participants in 
the referenced studies had initial sleep efficiency values of 65-70% (Kay et al., 2015; Miller et 
al., 2014). That is because these comparative studies evaluated participants diagnosed with 
insomnia, in contrast to the present study which only targeted individuals with self-reported sleep 
disruptions. The use of a less severe sample could explain smaller treatment effect on sleep 
efficiency. Even with the reduced severity of sleep impairment among study participants, 




If the present study findings replicate, probiotics may have considerable clinical utility in 
helping address disrupted sleep. Probiotics are easy to administer and consume. There is a large 
body of evidence suggesting that probiotics are safe and low-risk (see Doron & Snydman, 2015). 
They are also easily accessible. The probiotic used in this study is available over-the-counter. 
The same cannot be said for existing sleep treatments. Pharmaceutical sleep aids, like most 
pharmaceutical treatments, can have harmful side effects (Mallon, Broman, & Hetta, 2009). 
Psychological treatments are generally side-effect free but require substantial time and effort. 
Probiotics promise to avoid those consequences while maintaining a clinically-relevant 
therapeutic benefit. 
The potential utility of probiotics in treating sleep disturbance is consistent with the 
broader premise of a connection between the microbiome and mental health (Dinan et al., 2013). 
Probiotic microbes tend to temporarily colonize the gut after their ingestion (Alander et al., 
1999). This colonization can help restore a healthier, more adaptive microbial balance to the gut 
(Williams, 2010). In the case of this study, improvements in SOL and sleep efficiency can 
presumably be attributed to restored microbial balance. Even if the introduced microorganisms 
were not colonizing the gut, the results of this study suggest that probiotics are fulfilling a 
function not currently addressed by the microbiome. Either way, it appears that sleep disturbance 
can be alleviated through manipulation of the microbiome. 
Most importantly, this study emphasizes the role that lifestyle plays in mental health. If 
an imbalanced microbiome is involved in sleep disruption, then it is necessary to determine how 
this imbalance arises. A person’s microbiome develops early in life and is molded by lifestyle 
(Falony et al., 2016; Li et al., 2014). Further investigation into the microbiome may reveal 
methods to both address microbial imbalance and to prevent imbalance from arising in the first 
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place. It may turn out that the best way to treat sleep disturbance and other forms of mental 
illness in the future is to implement lifestyle changes targeting the microbiome.  
As mentioned previously, probiotic supplementation was only better than placebo in 
participants without elevated initial anxiety. Furthermore, the treatment effect increased as initial 
anxiety decreased. It should be noted that probiotic supplementation did not have a significant 
effect on anxiety in this study. This could account for the lack of effectiveness of probiotics in 
improving disrupted sleep in people with elevated initial anxiety. It was hypothesized that the 
sleep-related therapeutic effect of probiotics would be enhanced in individuals with high anxiety 
because of the purported anxiolytic properties of probiotics (Bercik et al., 2011; Luo et al., 
2014). By concomitantly addressing anxiety, probiotics would presumably have the potential to 
positively impact sleep through multiple mechanisms. In the absence of probiotic-induced 
anxiolysis, however, there is no hypothesized reason to suspect that initial anxiety would 
moderate the effect of probiotic supplementation. 
Given the findings from the present study, it is possible that anxiety interferes with 
probiotic-induced improvement in sleep. For example, stress is actually capable of altering the 
structure of the microbiome, and it can reduce microbial diversity and richness (Bailey et al., 
2011; Gur, Worly, & Bailey, 2015). Anxiety might reduce probiotic effectiveness in treating 
sleep disturbance by inducing more severe microbiome dysfunction. Accordingly, the use of 
adjuvant treatment approaches, such as an increased probiotic dosage or the use of different 
strains, may be needed to compensate for the inhibiting effect of anxiety. However, there is at 
present insufficient evidence to arrive at a definite conclusion. The relationship between sleep, 
anxiety, and probiotics is an area that has received little attention. Further research is needed to 
elucidate the role anxiety plays in regulating probiotic-induced sleep improvement.  
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 Despite the anxiety-related reduced effectiveness, it is important to emphasize that 
probiotics typically outperformed placebo at improving SOL and sleep efficiency among study 
participants across non-elevated initial anxiety levels. Past research has shown that only 37% of 
individuals with sleep problems also have a comorbid anxiety disorder (Roth et al., 2006). 
Furthermore, Ohayon, Caulet, and Lemoine (1998) reported that 54.3% of people with a 
diagnosis of primary insomnia do not experience symptoms of anxiety. It appears that a 
significant portion of people with sleep disturbance are not simultaneously suffering from 
anxiety. As such, probiotic supplementation has the potential to be a powerful effective 
therapeutic agent for this population. 
The final goal of this study was to help determine if a relationship exists between 
probiotic supplementation, sleep, and vagal tone. The vagus nerve is a major connection between 
the enteric and central nervous systems (Mayer, 2011). Hypothesis 3 predicted that probiotic-
related vagal tone improvement, measured through HF, would mediate improvement in sleep. 
Probiotic supplementation did not have an effect on HF, or PSQI-measured sleep. These findings 
fail to support a beneficial effect of probiotics on vagal tone. They also do not support vagal tone 
as a mechanism of action for improved sleep. Currently, no studies have examined the effect of 
probiotics on HRV. Because probiotics did not influence PSQI-measured sleep, it is difficult to 
rule out HF as a potential mediating variable. Further experimentation would be needed to 
thoroughly assess the role of the vagus nerve in probiotic-induced sleep improvement.  
The lack of vagal tone improvement could also help explain why the expected interaction 
between initial anxiety and treatment condition was not seen. There is evidence that probiotics 
can reduce anxiety through immune-based pathways (Smith et al., 2014). However, previous 
studies have also found that the anxiolytic properties of probiotics could be eliminated by 
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severing the vagus nerve (Bercik et al., 2011; Bravo et al., 2011). It is possible that the anxiolytic 
properties of probiotics rely primarily upon vagal pathways, rather than other branches of the 
microbiome-gut-brain axis. If so, addressing anxiety-related sleep disturbance would require the 
use of probiotics that can affect vagal tone.  
While vagal tone should remain a potential mechanism of interest, the results of this 
study suggest that it may not be related to the sleep-related therapeutic effects of probiotics. 
Other pathways within the microbiome-gut-brain axis should be examined for their role in 
regulating sleep disturbance. The microbiome prominently regulates both innate and adaptive 
immunologic responses within the body (Galland, 2014). There is evidence that inflammation 
and immune activation alters sleep architecture (for review see Ali, Choe, Awab, Wagener, & 
Orr, 2013). Microbiota are also capable of producing metabolites, hormones, and 
neurotransmitters that can influence the central nervous system (Galland, 2014). Any of these 
pathways could have been responsible for the improvement in SOL seen in this study.  
Limitations 
 There are potential limitations to the current findings. First, this study utilized a relatively 
short supplementation period. Previous studies investigating the psychotropic properties of 
probiotics have used a supplementation period of two weeks or longer (eg/ Benton et al., 2007; 
Yamamura et al., 2007). The two-week supplementation period used in this study falls on the 
short end of required probiotic administration and may have been insufficient to detect changes 
in HRV or psychological questionnaires.  
 Other limitations can be attributed to the methodological design of the study. Due to the 
small sample size, this study may not have been adequately powered to detect all of the 
meaningful effects of probiotic supplementation. The use of a non-clinical sample may have 
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contributed to this reduced power. This study could have also been improved through the use of 
objective sleep measures, such as actigraphy or polysomnography, as well as stronger 
supplementation adherence checks.  
A final limitation is the generalizability of the findings. As this study was part of a larger 
experiment, recruitment targeted participants with elevated symptoms of depression. It would be 
important to replicate these findings with a more heterogeneous sample.  
Future Directions 
 The next step is to follow up on the results of this study and determine if probiotics can 
influence objective measures of sleep disturbance. Examples of objective sleep measures include 
actigraphy. One benefit to using actigraphy is that it minimizes the influence of the placebo 
effect (Neukirch & Colagiuri, 2015). This would make it easier to identify unique effects of 
probiotics. 
 It is also necessary to determine if probiotics are inducing reliable change within the 
microbiome. It is assumed that probiotics provide benefits by restoring the microbiome to 
balance. However, without assessing the composition of the microbiome, this cannot be known 
for sure. This study provides rationale for assessing change in the composition of the 
microbiome following probiotic treatment for sleep disturbance. 
 Finally, it is important to determine how long probiotic-induced reductions in sleep 
disturbance last. Probiotics typically have transient effects, meaning that improvements in 
disrupted sleep may have a limited window of benefit (Alander et al., 1999). Establishing a 





This study provides evidence of the potentially important role that the microbiome plays 
in regulating psychological and physiological processes. It suggests that probiotic 
supplementation could be used to help reduce sleep disruption. Support for probiotics as a 
treatment for mental illness and related disorders is growing rapidly. Exploration of the 
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Table 1  
Participant characteristics 
 Overall Placebo Probiotic 
 (N = 43) (n = 20) (n = 23) 
Gender n (%)*    
Female 25 (58.1) 12 (60.0) 13 (56.5) 
Male 17 (39.5) 7 (35.0) 10 (43.5) 
Sleep Medication Usage n (%) 11 (25.6) 6 (30.0) 5 (21.7) 
Sleep Efficiency Initial % (SD) 89.2 (10.0) 88.7 (12.2) 89.6 (7.9) 
Mean (SD)    
Age in years 19.6 (3.2) 19.0 (1.5) 20.1 (4.2) 
Adherence (max = 14) 12.7 (2.7) 12.6 (3.3) 12.8 (2.1) 
SOL Initial Min 26.7 (26.0) 28.6 (28.3) 25.0 (24.2) 
Awakenings Initial 1.3 (1.4) 1.2 (1.2) 1.5 (1.6) 
WASO Initial Min 12.5 (20.1) 10.2 (12.2) 14.6 (25.2) 
PSQI Initial 8.6 (2.6) 8.5 (2.3) 8.7 (2.9) 
PSQI Final** 9.6 (2.2) 9.3 (2.0) 9.9 (2.3) 
STAI Initial 46.6 (10.3) 45.6 (10.6) 47.5 (10.1) 
STAI Final** 46.0 (10.2) 43.9 (9.5) 48.0 (10.6) 
BDI Initial 19.3 (7.0) 19.7 (7.8) 19.1 (6.4) 
BDI Final** 15.3 (6.07) 15.6 (6.7) 15.0 (5.6) 
HF Initial*** 457.1 (372.0) 514.9 (382.7) 402.2 (363.2) 
HF Final*** 500.4 (357.9) 547.9 (441.3) 455.3 (260.4) 
Note. SOL – Sleep onset latency; WASO – Wake after sleep onset; PSQI – Pittsburgh Sleep Quality 
Index; BDI – Beck Depression Inventory; STAI – State-trait Anxiety Inventory (state version) 





Sleep Onset Latency (SOL) and Sleep Efficiency Model Results 
 SOL Model Sleep Efficiency Model 
Parameter β (SE) β (SE) 
Intercept 2.771 (0.162) *** -0.109 (0.014) *** 
Level 1 (observation specific)   
Day -0.027 (0.014) * 0.003 (0.001) * 
Sleep Medication 0.406 (0.188) * -0.026 (0.018) 
Level 2 (participant specific)   
Condition 0.264 (0.222) -0.021 (0.019) 
STAI initial (centered) 0.015 (0.154)  -0.007 (0.013) 
Age (centered) -0.127 (0.100) 0.014 (0.008)  
Condition*STAI -0.188 (0.218) 0.022 (0.019) 
Cross-level interaction   
Day*Condition -0.005 (0.019) -0.001 (0.002) 
Day*STAI -0.027 (0.013) * 0.002 (0.001) 
Day*Condition*STAI 0.041 (0.018) * -0.004 (0.002) * 
Note. Estimates and standard errors (in parentheses). The fixed effects must first be 
exponentiated in order to yield interpretable likelihoods. 





Table 3  
Sleep Onset Latency (SOL) reduction (%) 
  Low anxiety   Average Anxiety  
 1 day 2 weeks 1 day 2 weeks 
Placebo 0.60 8.05 2.68 31.61 




Table 4  
Sleep Efficiency increase (%) 
  Low anxiety   Average Anxiety  
 1 day 2 weeks 1 day 2 weeks 
Placebo 0.10 1.40 0.29 4.17 






Figure 1. Effect of probiotic supplementation on sleep onset latency in participants with low 





Figure 2. Effect of probiotic supplementation on sleep efficiency for participants with low 
starting anxiety. 
 
